AJMC September 11, 2024
A new proof-of-concept method reliably engineered a hotspot mutation of SF3B1, a gene-splicing gene, into diverse cancer cell lines, outperforming other contemporary editing approaches.
SF3B1 remains one of the more frequent and recurrent mutated RNA-splicing genes in cancer. Yet, a lack of disease-relevant cell line models have hindered clinical understandings of its pathologic role. A novel approach to gene editing provides insights into the role of SF3B1 in cancer, according to research published in Cancer Research Communications.1
Oncogenesis associated with hotspot mutations in SF3B1 has been observed throughout a multitude of cancers. New advances in gene editing promises to revolutionize cancer research with precise and accurate modeling of specific point mutations, the authors wrote. This is especially relevant for SF3B1,...
Today's Sponsors
Today's Sponsor